Camzyos, which works by blocking the actin-myosin interactions responsible for HCM and, in effect, relaxing the heart, bears ...
SCOUT-HCM demonstrated the superiority of Camzyos on the primary endpoint and multiple secondary endpointsThe overall safety results in this study were consistent with the established safety profile ...
Princeton, New Jersey Wednesday, January 14, 2026, 12:00 Hrs [IST] ...
Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...
The U.S. health regulator asked drugmakers on Tuesday to remove warnings about a potential risk of suicidal thoughts from ...
The FDA has approved Zycubo (copper histidinate) injection as the first and only treatment of Menkes disease in pediatric ...
Mavacamten is a selective, reversible, allosteric cardiac myosin inhibitor. It is approved under the brand name Camzyos ® for the treatment of adults with symptomatic New York Heart Association class ...
Friendly” labels on the packaging are becoming more common as a growing number of Americans try obesity drugs like Wegovy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback